Methods: A comprehensive literature search was performed across multiple medical databases, including Embase, Medline, and Cochrane to look for English articles on interventions with SGLT2 inhibitors, GLP-1, and dual gastric inhibitory polypeptide/GLP-1 receptor agonists in people living with sleep apnea and overweight or obesity
Research in this area is still evolving, but early findings suggest several potential benefits: Improved Mood and Reduced Depression Symptoms: Some studies have indicated that GLP-1 receptor agonists might have antidepressant-like effects
This means more frequent vomiting episodes and greater nutrient loss through the GI tract during dose titration
Studies have shown that GLP-1 can be used for treatment of cardiac diseases, possibly independent of their effect in obesity [33] (Fig
It works by replicating the bodys natural hormone GLP-1, which is responsible for regulating appetite, digestion, and blood sugar balance